NKの治療のための0.1%RGN-259点眼液の安全性と有効性の評価:SEER-2
神経栄養性角膜症(SEER-2)の治療のための0.1%RGN-259点眼液の安全性と有効性を評価するための第3相、多施設、無作為化、並行、二重マスク、プラセボ対照臨床試験
The objective of this study is to compare the safety and efficacy of RGN-259 to placebo for the treatment of Neurotrophic Keratopathy (NK)
調査の概要
詳細な説明
Neurotrophic keratopathy (NK) is a degenerative corneal disease that occurs as a result of partial or total impairment of trigeminal innervation. The resulting loss of corneal sensitivity (anesthesia) leads to a reduction in lacrimation and a decline in status, metabolism, and mitosis of corneal epithelial cells.
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Alabama
-
Vestavia Hills、Alabama、アメリカ、35242
- Parker Cornea
-
-
California
-
Laguna Hills、California、アメリカ、92653
- Harvard Eye Associates
-
Loma Linda、California、アメリカ、92354
- Loma Linda University Eye Institute
-
Los Angeles、California、アメリカ、90013
- Nvision Clinical Research, LLC
-
-
Colorado
-
Colorado Springs、Colorado、アメリカ、80909
- Retina Consultants of Southern Colorado
-
Longmont、Colorado、アメリカ、80503
- Advance Vision Research Institute
-
-
Connecticut
-
Danbury、Connecticut、アメリカ、06810
- Connecticut Eye Consultants, P.C. Danbury Eye Physicians & Surgeons
-
-
Florida
-
Crystal River、Florida、アメリカ、34429
- Nature Coast Clinical Research
-
Miami、Florida、アメリカ、33136
- University of Miami - Bascom Palmer Eye Institute, Miami
-
Tampa、Florida、アメリカ、33612
- University of South Florida, Ophthalmolgoy
-
-
Georgia
-
Sandy Springs、Georgia、アメリカ、30328
- Thomas Eye Group, P.C.
-
-
Illinois
-
Chicago、Illinois、アメリカ、60611
- Northwestern
-
-
Indiana
-
Carmel、Indiana、アメリカ、46290
- Midwest Cornea Associates, LLC.
-
-
Kentucky
-
Lexington、Kentucky、アメリカ、40509
- Huffman & Huffman, PSC
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21287
- The Johns Hopkins Wilmer Eye Institute
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02111
- Tufts Medical Center
-
-
Missouri
-
Chesterfield、Missouri、アメリカ、63017
- Midwest Vision Research Foundation
-
St Louis、Missouri、アメリカ、63108
- Washington University Eye Center
-
-
New Jersey
-
Eatontown、New Jersey、アメリカ、07724
- Atlantic Eye
-
Palisades Park、New Jersey、アメリカ、07650
- Metropolitan Eye Research and Surgery Institute
-
-
New York
-
The Bronx、New York、アメリカ、10467
- Montefiore Medical Center
-
-
North Carolina
-
Durham、North Carolina、アメリカ、27710
- Duke Eye Center
-
Raleigh、North Carolina、アメリカ、27617
- Oculus Research
-
Shelby、North Carolina、アメリカ、28150
- CORE, Inc. / Vita Eye Clinic
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44106
- University Hospitals Cleveland Medical Center
-
Cleveland、Ohio、アメリカ、44195
- Cleveland Clinic, Cole Eye Institute
-
-
Oregon
-
Eugene、Oregon、アメリカ、97401
- Pacific ClearVision Institute
-
Medford、Oregon、アメリカ、97504
- Cataract & Laser Institute of Southern Oregon
-
Portland、Oregon、アメリカ、97239
- OHSU Casey Eye Institute
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- Scheie Eye Institute, University of Pennsylvania
-
Pittsburgh、Pennsylvania、アメリカ、15213
- UPMC Eye Center
-
-
South Dakota
-
Rapid City、South Dakota、アメリカ、57701
- Black Hills Regional Eye Institute
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37232
- Vanderbilt Eye Institute
-
-
Texas
-
Dallas、Texas、アメリカ、75231
- Cornea Associates of Texas
-
Houston、Texas、アメリカ、77025
- Houston Eye Associates
-
Mission、Texas、アメリカ、78572
- CliniVerse Research
-
San Antonio、Texas、アメリカ、78212
- Stuart Terry Eye Associates
-
San Antonio、Texas、アメリカ、78240
- MCOA Eye Care
-
Sugar Land、Texas、アメリカ、77478
- Berkeley Eye Center
-
-
Virginia
-
Norfolk、Virginia、アメリカ、23502
- Virginia Eye Consultants
-
-
Washington
-
Seattle、Washington、アメリカ、98104
- University of Washington, Department of Ophthalmology
-
-
-
-
Brescia
-
Brescia、Brescia、イタリア、25123
- Università di Brescia
-
-
Firenze
-
Florence、Firenze、イタリア、50134
- Azienda Ospedaliero Universitaria Careggi
-
-
Lombardy
-
Milan、Lombardy、イタリア、20132
- Ospedale San Raffaele s.r.l.
-
Milan、Lombardy、イタリア、20142
- Università degli Studi di Milano - ASST Santi Paolo e Carlo
-
-
-
-
Barcelona
-
Barcelona、Barcelona、スペイン、08035
- IMO Barcelona, Grupo Miranza
-
-
Córdoba
-
Córdoba、Córdoba、スペイン、14012
- Hospital La Arruzafa
-
-
Principality of Asturias
-
Oviedo、Principality of Asturias、スペイン、33012
- Instituto Oftalmológico Fernández-Vega
-
-
Valencia
-
Valencia、Valencia、スペイン、46004
- Aiken Prevención & Cirugía Ocular
-
-
-
-
Silesian Voivodeship
-
Katowice、Silesian Voivodeship、ポーランド、40-594
- Gabinet Okulistyczny Prof Edward Wylegala
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria
- Be male or female of any race, at least 18 years of age;
- Have provided written informed consent;
- Be able and willing to follow instructions, including participation in all study assessments and visits;
- At the time of Visit 1, have documentation or observation of a Persistent Epithelial Defect (PED) in one or both eyes, defined as a corneal epithelial defect that has not resolved after 1 week of conventional treatment using non-preserved ocular lubricants, non-preserved topical ophthalmic antibiotics, oral doxycycline, patching, amniotic membrane, serum tears, and/or therapeutic contact lenses;
- Have stage 2 or 3 neurotrophic keratopathy (Mackie Classification) in at least one eye of which the longest dimension (length or width) of the defect measures a minimum length of 1 mm (study eye) and which is confirmed by the Investigator not to be simply superficial punctate keratitis, at Visit 1;
- Have evidence of decreased corneal sensitivity ≤40 mm using the Cochet-Bonnet aesthesiometer at Visit 1;
- Have BCVA score ≤75 letter counts in the study eye based on the ETDRS protocol;
- Have at least one eye (the same eye) satisfy all criteria for d, e, f, g above;
- Female subjects of child-bearing potential must be non-lactating and using and agree to continue using an acceptable method of contraception for at least 4 weeks prior to the first dose of study product and until 12 weeks after last dose, and have a negative urine pregnancy test during screening;
- Male subjects must agree to use an adequate method of contraception.
Exclusion Criteria
- Have any condition that, in the opinion of the Investigator, would interfere with the subject's ability to complete the study, would interfere with the interpretation of safety or efficacy, or would present an undue risk to the subject.
- Have any clinically significant slit-lamp findings in the study eye that in the opinion of the Investigator may interfere with the study parameters;
- Clinically significant active blepharitis, meibomian gland dysfunction (MGD), or lid margin inflammation, or active ocular allergy in study eye that requires treatment that in the opinion of the investigator may interfere with the study parameters;
- Have a Unanesthetized Schirmer's test score of ≤3 mm at Visit 1;
- Have a lid function abnormality (ex. Lagophthalmos) which, in the opinion of the Investigator, is the primary cause of the persistent epithelial defect;
- Have an ongoing ocular infection (bacterial, viral or fungal) or active inflammation (e.g., follicular conjunctivitis) in the study eye.
- History of any ocular surgery (including laser or refractive surgical procedures) within the three months before study enrollment.
- Prior surgical procedure(s) for the treatment of NK (e.g., tarsorrhaphy, conjunctival flap, etc.) within the three months before study enrollment with the exception of amniotic membrane transplantation.
- Have any planned ocular surgical procedures or are likely to require ocular surgery for the study eye during the study;
- Have received Botox® injection to induce blepharoptosis in the study eye within 90 days prior to Visit 1;
- Have used contact lenses (for therapeutic or refractive correction) in the study eye within 14 days prior to Visit 1, or anticipate use of contact lenses during the study period.
- Have used OxervateTM in the study eye within the past 2 months;
- Anticipate use of serum tears in the study eye during the study period.
- Have a presence or history of any ocular or systemic disorder or condition that might hinder the efficacy of the study treatment or its evaluation, could possibly interfere with the interpretation of study results, or could be judged by the Investigator to be incompatible with the study visit schedule or conduct;
- Have used drugs which affect lacrimation or function of the trigeminal nerve within 30 days of Visit 1 or anticipate use of these systemic medication throughout the course of the study;
- Have any autoimmune or chronic inflammatory disease that might have hindered the efficacy of the study treatment or its evaluation;
- Be on topical (Ocular/Nasal) immunosuppressive therapy within 30 days prior to screening or is likely to require this during the course of the study;
- Have a known allergy and/or sensitivity to the study product or its components;
- History of drug, medication or alcohol abuse or addiction;
- Have participated in an investigational drug study within 30 days prior to screening;
- Have fever, inflammation, or systemic signs of illness suggestive of systemic or invasive infection, including COVID-19 or a positive test for COVID-19, within 2 weeks prior to first dose of study drug.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:0.1% RGN-259 Opthalmic Solution
It is a preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into study eye(s), five times per day for 28 days |
A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into study eye(s), five times per day for 28 days
他の名前:
|
|
プラセボコンパレーター:Placebo Ophthalmic Solution (Vehicle for RGN-259 Ophthalmic Solution)
It is composed of the same excipients as RGN-259 but does not contain Tβ4 |
It is composed of the same excipients as RGN-259 but does not contain Tβ4. Direct instillation into study eye(s), five times per day for 28 days
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of subjects achieving complete healing of PED at Day 29
時間枠:Day 29
|
Percentage of subjects achieving complete healing of the Persistent Epithelial Defect (PED) at Day 29 determined by corneal fluorescein staining as measured by the Central Reading Center. |
Day 29
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Cochet Bonnet aesthesiometer による病変内部の角膜感度 (単位: mm)
時間枠:8日目、15日目、22日目、29日目、36日目、43日目
|
8日目、15日目、22日目、29日目、36日目、43日目
|
|
|
Percentage of subjects achieving complete healing of PED at Day 29
時間枠:Day 29
|
Percentage of subjects achieving complete healing of the PED determined by corneal fluorescein staining as measured by the Investigator. |
Day 29
|
|
Percentage change from baseline of lesion size
時間枠:Day 8, 15, 22, 29, 36, and 43
|
Percentage change from baseline of lesion size determined by corneal fluorescein staining (measurements of greatest dimension of fluorescein staining) |
Day 8, 15, 22, 29, 36, and 43
|
|
NK stage by Mackie classification
時間枠:Day 8, 15, 22, 29, 36, and 43
|
NK stage graded according to the Mackie classification (Stage I, II, III. Higher scores mean a better or worse outcome) |
Day 8, 15, 22, 29, 36, and 43
|
|
Visual Acuity determined by ETDRS
時間枠:Day 8, 15, 22, 29, 36, and 43
|
Visual Acuity determined by Early Treatment of Diabetic Retinopathy Study (ETDRS) |
Day 8, 15, 22, 29, 36, and 43
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
眼圧(単位:mmHg)
時間枠:1日目、8日目、29日目、43日目
|
1日目、8日目、29日目、43日目
|
|
|
Frequency and severity of AEs
時間枠:Day 8, 15, 22, 29, 36, and 43
|
Frequency and severity of AEs as reported according to the NCI CTCAE version 5.0 |
Day 8, 15, 22, 29, 36, and 43
|
|
Number of participants with abnormal vital signs
時間枠:Day 1, 8, 15, 22, 29, 36, and 43
|
Blood pressure, heart rate, respiratory rate, oxygen saturation, and body temperature will be measured and assessed its clinical abnormality. |
Day 1, 8, 15, 22, 29, 36, and 43
|
|
Dilated fundoscopy (Vitreous, Retina, Macula, Choroid, Optic Nerve)
時間枠:Day 1, 8, 29 and 43
|
The fundoscopy exam will be performed and clinical abnormality of vitreous, retina, Macula, Choroid and Optic Nerve will be described. |
Day 1, 8, 29 and 43
|
|
Slit-lamp biomicroscopy (Cornea, Conjunctiva, Anterior Chamber, Iris, Lens, Lid)
時間枠:Day 1, 8, 15, 22, 29, 36, and 43
|
The Slit-Lamp biomicroscopy will be performed and clinical abnormality of Cornea, Conjunctiva, Anterior Chamber, Iris, Lens and Lid will be described. |
Day 1, 8, 15, 22, 29, 36, and 43
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。